Davis et al. 2020: Ibogaine + 5-MeO-DMT for Veterans’ Trauma-Related Symptoms (Observational Survey)

Definition box

Definition: Davis A.K., Averill L.A., Sepeda N.D., Barsuglia J.P., Amoroso T. (2020) in *Chronic Stress* (doi: 10.1177/2470547020939564) is a retrospective observational survey of U.S. Special Operations Forces (SOF) veterans who completed a Mexico clinical program (2017–2019) using sequential psychoactive dosing: a single oral dose of ibogaine hydrochloride (10 mg/kg) with continuous cardiac monitoring and IV fluids, then later inhaled 5-MeO-DMT (multi-dose session). Of 65 eligible completers, n = 51 (78%) answered questions comparing the 30 days before vs 30 days after treatment. Authors reported large retrospective self-report reductions in PTSD, depression, anxiety, cognitive impairment, and suicidal ideation, plus increased psychological flexibility—and explicitly labeled findings preliminary (no randomization, no blinding, survey design). This paper is oral ibogaine + sequential 5-MeO-DMT program evaluation—not proof of physician-supervised IV ibogaine infusion (psychoactive intravenous ibogaine) efficacy, and not a cure claim. Ibogaine is U.S. Schedule I and not FDA-approved. QTc/cardiac risk remains central to any ibogaine discussion.

Quotable answer (58 words)

Davis and colleagues’ 2020 Chronic Stress survey of 51 SOF veterans found large retrospective symptom reductions after oral ibogaine then inhaled 5-MeO-DMT in a Mexico program. Design limits—self-report, no randomization—make findings preliminary. It does not prove psychoactive IV ibogaine infusion efficacy. Screen for QTc risk first. Not FDA-approved.

Why this paper-spoke exists

Search and clinic marketing often compress this paper into:

> “Ibogaine cured veterans’ PTSD—Stanford/SOF proved it.”

That compression fails on attribution, route, design, and combination therapy. Davis 2020 is a named survey of a sequential oral-ibogaine + 5-MeO-DMT program, not an IV-psychoactive RCT and not a license for consumer cure language. Pair with MISTIC oral+IV-magnesium teaching (/blog/stanford-ibogaine-mistic), PTSD condition page (/ibogaine-for-ptsd), and 5-MeO comparison (/blog/ibogaine-vs-5-meo-dmt). Soft CTA path: /safety-and-screening → /apply.

What was studied

| Feature | Accurate description | |---------|----------------------| | Citation | Davis A.K., Averill L.A., Sepeda N.D., Barsuglia J.P., Amoroso T. Psychedelic treatment for trauma-related psychological and cognitive impairment among US Special Operations Forces veterans. *Chronic Stress*. 2020;4:2470547020939564. doi 10.1177/2470547020939564 | | Type | Retrospective observational survey / program evaluation | | Setting | Residential clinical program in Mexico (2017–2019) | | Population | U.S. SOF veterans (mean age ~40; ~96% male; largely OEF/OIF) | | Analytic N | 51 of 65 eligible completers (78% response) | | Psychoactive sequence | Day 1: oral ibogaine HCl 10 mg/kg (reported 99% purity) with continuous cardiac monitoring + IV fluids; Day 2: integration; Day 3: inhaled 5-MeO-DMT (escalating multi-dose protocol as described by authors) | | Outcomes window | Retrospective 30 days pre vs 30 days post (time since treatment varied ~1 month–2 years) | | Key domains | PTSD, depression, anxiety, cognitive impairment, suicidal ideation, psychological flexibility; subjective meaningfulness ratings |

Methods (plain language)

Veterans who already completed the program were later surveyed about symptoms in the month before and after treatment. Screening in the clinical program (as described) included physician medical review, psychiatric intake, labs (CBC, metabolic panel, urine drug screen), 12-lead ECG, and stress testing for selected higher-risk patients; contraindicated medications required pharmacist-designed tapering. The research design itself was not a randomized controlled trial: there was no placebo arm, no blinding, and outcomes were retrospective self-report. Combined sequential dosing means effects cannot be cleanly attributed to ibogaine alone, 5-MeO-DMT alone, or their interaction.

Key findings (no hype)

Authors reported (all retrospective self-report; large effect sizes as published):

• Significant reductions in suicidal ideation, cognitive impairment, PTSD, depression, and anxiety symptom scores (before-to-after).
• Significant increase in psychological flexibility, which correlated with larger symptom reductions.
• High rates rating experiences among top-five personally meaningful / spiritually significant / psychologically insightful life experiences.
• Authors’ own framing: findings are preliminary; randomized, double-blind, placebo-controlled trials are warranted.
• The paper as published did not provide a full adverse-event incidence package comparable to a prospective safety RCT—do not invent one.

Honest reading: large survey effect sizes in a motivated SOF cohort generate research interest; they do not equal FDA-grade efficacy, do not prove durability for every reader, and do not prove any specific clinic’s IV brand protocol.

A later related prospective open-label program-evaluation paper (Davis et al., *Am J Drug Alcohol Abuse* 2023; doi 10.1080/00952990.2023.2220874) extends the same sequential model with follow-up timepoints—still not psychoactive IV proof and still not a cure claim. Keep citations distinct.

Limits and confounders

| Limit / confounder | Why it matters | |--------------------|----------------| | Retrospective survey | Memory bias; expectancy; “after” window may be idealized | | No randomization / no blinding | Cannot isolate drug effect from setting, staff, or placebo-like expectancy | | Combined sequential model | Cannot attribute outcomes to ibogaine vs 5-MeO-DMT vs synergy vs therapy | | Self-selection / word-of-mouth referral | Healthier, wealthier, or more treatment-ready veterans may dominate | | Incomplete response (51/65) | Non-responders may differ systematically | | Variable time-since-treatment | Mixing 1-month and 2-year recall weakens causal clarity | | Mostly male SOF sample | Limited generalizability to other genders/civilian trauma | | Oral ibogaine route | Not evidence for psychoactive IV ibogaine infusion | | Safety/AE under-measurement risk | Symptom benefit narrative ≠ full cardiac safety dossier | | Not a cure trial | No license for “cures PTSD” marketing |

Route honesty: oral ≠ psychoactive IV

Davis 2020’s psychoactive ibogaine was oral HCl 10 mg/kg. Continuous cardiac monitoring and IV fluids during the oral session are support/monitoring—not psychoactive intravenous ibogaine. Do not conflate with:

• Brand IV ibogaine infusion = physician-supervised psychoactive IV dosing entity on this site (/what-is-ibogaine-infusion, /blog/ibogaine-oral-vs-iv)
• MISTIC-style oral ibogaine + IV magnesium (/blog/stanford-ibogaine-mistic, /blog/magnesium-ibogaine-cardiac-protocol) — support IV ≠ psychoactive IV

Oral observational signals do not automatically transfer to IV kinetics, exposure curves, or risk profiles. Cardiac biology (QTc) still applies.

Cardiac / YMYL context

Even when a survey emphasizes mental-health signals, ibogaine’s QTc prolongation and arrhythmia risk remain non-negotiable:

• Oral QTc magnitude teaching: /blog/knuijver-2021-ibogaine-qtc-safety
• CYP2D6 / PK variability: /blog/knuijver-2024-ibogaine-pk-cyp2d6, /blog/ibogaine-cyp2d6-metabolism
• CV complications teaching: /blog/ibogaine-cardiovascular-complications-review
• Setting/monitoring map: /blog/ibogaine-setting-factors-safety-review-2023
• Pre-infusion ECG checklist: /blog/ibogaine-ecg-pre-infusion-checklist
• Contraindications: /blog/ibogaine-contraindications

A veterans-marketing page that never mentions ECG/telemetry fails YMYL honesty.

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Davis 2020 proved IV ibogaine for PTSD” | False — oral + sequential 5-MeO; survey design | | “SOF data = FDA approval / cure” | False | | “Large d = guaranteed personal outcome” | False | | “IV fluids during oral session = psychoactive IV” | False | | Cite as oral sequential observational signal with named confounders? | Yes |

U.S. Schedule I / not FDA (/blog/is-ibogaine-legal-us). Veterans/Right-to-Try context is separate legal framing—not efficacy proof (/blog/ibogaine-right-to-try-veterans).

Soft CTA

If you are a veteran or family member comparing medically supervised options, read Davis 2020 as hypothesis-generating oral + 5-MeO program data, not as a promise. Start with cardiac and psychiatric screening education at /safety-and-screening, then /apply only if exploring physician-supervised IV ibogaine infusion questions. Entity: /what-is-ibogaine-infusion.

FAQ

What is the Davis 2020 paper? A retrospective survey in *Chronic Stress* of 51 U.S. SOF veterans after a Mexico program using oral ibogaine then inhaled 5-MeO-DMT (doi 10.1177/2470547020939564).

Was the ibogaine oral or IV? **Oral** ibogaine HCl (~10 mg/kg). IV fluids and cardiac monitoring were supportive—not psychoactive IV ibogaine.

Does this prove IV ibogaine infusion works? No. It is observational survey data on a sequential oral-ibogaine + 5-MeO-DMT model, not an IV psychoactive efficacy RCT.

Why can’t we credit ibogaine alone? The program used **sequential** ibogaine and 5-MeO-DMT plus preparation/integration support—effects are confounded.

Did authors call results definitive? No—they described findings as preliminary and called for controlled trials.

Does large effect size mean a cure? No. Self-report retrospective surveys can inflate apparent benefit; this site does not make cure claims.

Should cardiac screening still happen? Yes. Ibogaine can prolong QTc; ECG and medical screening remain essential (/safety-and-screening).

Is ibogaine FDA-approved? No. Schedule I in the U.S.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Davis 2020 is oral sequential observational survey literature—not psychoactive IV ibogaine efficacy proof and not a cure claim.

Sources (selected)

1. Davis A.K., Averill L.A., Sepeda N.D., Barsuglia J.P., Amoroso T. Psychedelic treatment for trauma-related psychological and cognitive impairment among US Special Operations Forces veterans. *Chronic Stress*. 2020;4:2470547020939564. doi: 10.1177/2470547020939564.
2. Davis A.K., Xin Y., Sepeda N., Averill L.A. Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico. *Am J Drug Alcohol Abuse*. 2023;49(5):587–596. doi: 10.1080/00952990.2023.2220874.
3. Cherian K.N. et al. *Nature Medicine*. 2024 — MISTIC oral ibogaine + IV magnesium (distinct protocol; not IV-psychoactive proof).
4. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).